[APAC] Advancing Clinical Trials with Decentralised Elements in Singapore
Exploring readiness, improving patient access and shaping a practical path forward
Clinical trials with decentralised elements can bring research closer to patients through remote participation, digital data collection and more flexible trial activities. Realising this potential requires careful consideration of participant safety, data integrity and operational feasibility.
This whitepaper from the Singapore Clinical Research Institute (SCRI), with contributions from Medidata, examines Singapore’s readiness to adopt these approaches more widely. Drawing on global experience and local perspectives, it explores the regulatory, technology and operational foundations needed to support responsible, scalable adoption.
What you’ll learn
- How decentralised elements can improve patient access and support participation in clinical research.
- Where Singapore stands across regulatory, technology, investigator site and patient readiness.
- Key considerations for implementation, including fit-for-purpose technology, connected workflows and proportionate risk management.
- A phased roadmap to guide adoption and strengthen collaboration across Singapore’s clinical research ecosystem.
Medidata’s contribution
Invited by SCRI as the whitepaper’s exclusive industry contributor, Medidata brought global experience and practical insights into how technology can support clinical trials with decentralised elements—from remote participation and digital data collection to connected workflows and oversight of trial quality.
Download the whitepaper
Complete the form to explore the findings and recommendations for advancing clinical trials with decentralised elements in Singapore.